[go: up one dir, main page]

PL1753723T3 - Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych - Google Patents

Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych

Info

Publication number
PL1753723T3
PL1753723T3 PL05752901T PL05752901T PL1753723T3 PL 1753723 T3 PL1753723 T3 PL 1753723T3 PL 05752901 T PL05752901 T PL 05752901T PL 05752901 T PL05752901 T PL 05752901T PL 1753723 T3 PL1753723 T3 PL 1753723T3
Authority
PL
Poland
Prior art keywords
substituted quinoline
quinoline derivatives
mitotic kinesin
kinesin inhibitors
compounds
Prior art date
Application number
PL05752901T
Other languages
English (en)
Inventor
W ; Wang
R ; Constantine
L ; Lagniton
K ; Bair
Original Assignee
Novartis Vaccines & Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostics Inc filed Critical Novartis Vaccines & Diagnostics Inc
Publication of PL1753723T3 publication Critical patent/PL1753723T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05752901T 2004-05-21 2005-05-19 Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych PL1753723T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57312004P 2004-05-21 2004-05-21
EP05752901A EP1753723B1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors
PCT/US2005/017961 WO2005113507A1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
PL1753723T3 true PL1753723T3 (pl) 2009-01-30

Family

ID=34970815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05752901T PL1753723T3 (pl) 2004-05-21 2005-05-19 Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych

Country Status (19)

Country Link
US (2) US7452996B2 (pl)
EP (1) EP1753723B1 (pl)
JP (1) JP2008502721A (pl)
CN (1) CN1956960A (pl)
AT (1) ATE404536T1 (pl)
AU (1) AU2005245492A1 (pl)
BR (1) BRPI0511433A (pl)
CA (1) CA2564215A1 (pl)
DE (1) DE602005008953D1 (pl)
DK (1) DK1753723T3 (pl)
ES (1) ES2311992T3 (pl)
HR (1) HRP20080493T3 (pl)
MX (1) MXPA06011958A (pl)
PL (1) PL1753723T3 (pl)
PT (1) PT1753723E (pl)
RS (1) RS50670B (pl)
RU (1) RU2385867C2 (pl)
SI (1) SI1753723T1 (pl)
WO (1) WO2005113507A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
RU2447077C2 (ru) 2004-08-18 2012-04-10 Астразенека Аб Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SI1965823T1 (sl) * 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
KR20090081020A (ko) * 2006-11-13 2009-07-27 노파르티스 아게 Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물
KR20090097210A (ko) * 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
MX2012011910A (es) * 2010-04-15 2012-11-29 Novartis Ag Compuestos de triazol como inhibidores de ksp.
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
US20150231117A1 (en) * 2012-08-13 2015-08-20 Array Biopharma Inc. Arry-520 for use in treating cancer in a patient with low aag
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
EP3338778A4 (en) * 2015-08-19 2019-04-17 Eisai R&D Management Co., Ltd. THERAPEUTICS FOR GALLENGER CARCINOMA
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
CA2369549A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002028839A1 (en) 2000-10-06 2002-04-11 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
EA007538B1 (ru) 2000-12-11 2006-10-27 Туларик Инк. Антагонисты cxcr3
EP1360180A1 (en) 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002351183B2 (en) 2001-12-06 2008-05-08 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
CN100381437C (zh) * 2002-04-17 2008-04-16 赛特凯恩蒂克公司 化合物、组合物和方法
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
KR20050036911A (ko) 2002-05-09 2005-04-20 싸이토키네틱스, 인코포레이티드 화합물들, 방법 및 조성물
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60329756D1 (de) 2002-06-14 2009-12-03 Merck & Co Inc Mitotische kinesin-hemmer
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
US20060134767A1 (en) 2002-07-08 2006-06-22 Buser-Doepner Carolyn A Mitotic kinesin binding site
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.

Also Published As

Publication number Publication date
JP2008502721A (ja) 2008-01-31
EP1753723A1 (en) 2007-02-21
CN1956960A (zh) 2007-05-02
SI1753723T1 (sl) 2009-04-30
RU2006145336A (ru) 2008-06-27
ATE404536T1 (de) 2008-08-15
ES2311992T3 (es) 2009-02-16
PT1753723E (pt) 2008-11-19
RS50670B (sr) 2010-06-30
CA2564215A1 (en) 2005-12-01
US20090028858A1 (en) 2009-01-29
DE602005008953D1 (de) 2008-09-25
BRPI0511433A (pt) 2007-12-11
WO2005113507A1 (en) 2005-12-01
DK1753723T3 (da) 2008-10-20
RU2385867C2 (ru) 2010-04-10
HRP20080493T3 (hr) 2009-02-28
AU2005245492A1 (en) 2005-12-01
EP1753723B1 (en) 2008-08-13
US7452996B2 (en) 2008-11-18
MXPA06011958A (es) 2006-12-15
US20050261337A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
TW200612958A (en) Substituted imidazole derivatives
MX2007004699A (es) Derivados de indol y bencimidazol.
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
TW200801000A (en) Spiroindolinone derivatives
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
TW200728307A (en) Novel spirochromanone derivatives
TW200833675A (en) Nicotinamide derivatives
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MX2012003982A (es) Pirrolidinas n-substituidas.
IL193620A0 (en) Spiroindolinone derivatives
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY156955A (en) Antifungal agents
WO2007017728A3 (en) Novel heterocyclic compounds